The Global Leader in Preclinical Ophthalmic Research

EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities.  Our models are well-established and optimized to facilitate generation of reproducible datasets with meaningful endpoints. With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals.  We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS®.

Microemulsion Drug Ocular Penetration System

MiDROPS®

MiDROPS® was developed to allow for eyedrop formulations of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment.  Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.

News & Events

News

EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration

“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release

News

EyeCRO scientist contributes to a paper published in Experimental Eye Research

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor

View All Posts

EyeCRO on Twitter

The first clinical application of MiDROPS® shows outstanding safety and tolerability, combined with therapeutic delivery! #ARVO2024 #dryeye

Paradigm changing for an ophthalmic microemulsion!

Contact us to formulate your next topical ophthalmic development project with MiDROPS®

Scientists at EyeCRO swapped lab coats for game controllers at our latest team outing in Ann Arbor!
Turns out, our skills in precision, observation, and hypothesis testing are also perfect for dominating at Best in Games. Thanks to the ringmaster @JCHarmanLSU #GamerScientists

4

.@DrSyMoroi hopes to decrease the amount of glaucoma-related blindness, working with other teams on projects designed to customize each patient’s glaucoma treatment plan.

#WomenInScience

Load More...